Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Depression and chronic pain in the elderly: links and management challenges.

Zis P, Daskalaki A, Bountouni I, Sykioti P, Varrassi G, Paladini A.

Clin Interv Aging. 2017 Apr 21;12:709-720. doi: 10.2147/CIA.S113576. eCollection 2017. Review.

2.

Distinct Antidepressant-Like and Cognitive Effects of Antidepressants with Different Mechanisms of Action in Middle-Aged Female Mice.

Li Y, Sanchez C, Gulinello M.

Int J Neuropsychopharmacol. 2017 Jun 1;20(6):510-515. doi: 10.1093/ijnp/pyx004.

3.

The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.

McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK.

Int J Neuropsychopharmacol. 2016 Aug 24. pii: pyw055. doi: 10.1093/ijnp/pyw055. [Epub ahead of print]

4.

Behavioral Health and Primary Care: A Status Report.

Culpepper L.

Prim Care Companion CNS Disord. 2016 Mar 3;18(1). doi: 10.4088/PCC.16ed01944. eCollection 2016. No abstract available.

5.

Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and Management.

Jaracz J, Gattner K, Jaracz K, Górna K.

CNS Drugs. 2016 Apr;30(4):293-304. doi: 10.1007/s40263-016-0328-5. Review.

6.

The 5-HT1A receptor in Major Depressive Disorder.

Kaufman J, DeLorenzo C, Choudhury S, Parsey RV.

Eur Neuropsychopharmacol. 2016 Mar;26(3):397-410. doi: 10.1016/j.euroneuro.2015.12.039. Epub 2016 Jan 11. Review.

7.

Cognitive remission: a novel objective for the treatment of major depression?

Bortolato B, Miskowiak KW, Köhler CA, Maes M, Fernandes BS, Berk M, Carvalho AF.

BMC Med. 2016 Jan 22;14:9. doi: 10.1186/s12916-016-0560-3. Review.

8.

Utility of the Neurobehavioral Cognitive Status Examination (COGNISTAT) in differentiating between depressive states in late-life depression and late-onset Alzheimer's disease: a preliminary study.

Tsuruoka Y, Takahashi M, Suzuki M, Sato K, Shirayama Y.

Ann Gen Psychiatry. 2016 Jan 20;15:3. doi: 10.1186/s12991-016-0091-5. eCollection 2016.

9.

Development of a Korean Version of the Perceived Deficits Questionnaire-Depression for Patients with Major Depressive Disorder.

Kim JM, Hong JP, Kim SD, Kang HJ, Lee YS.

Clin Psychopharmacol Neurosci. 2016 Feb 29;14(1):26-32. doi: 10.9758/cpn.2016.14.1.26.

10.

Influence of Pharmacotherapy on Cognitive Functions in Depression: A Review of the Literature.

Orzechowska A, Filip M, Gałecki P.

Med Sci Monit. 2015 Nov 24;21:3643-51. Review.

11.

Deconstructing Chronic Low Back Pain in the Older Adult: Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part IV: Depression.

Carley JA, Karp JF, Gentili A, Marcum ZA, Reid MC, Rodriguez E, Rossi MI, Shega J, Thielke S, Weiner DK.

Pain Med. 2015 Nov;16(11):2098-108. doi: 10.1111/pme.12935. Epub 2015 Nov 5. Review.

12.

Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.

Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, Dew MA, Butters MA, Stack JA, Begley AE, Reynolds CF 3rd.

Lancet. 2015 Dec 12;386(10011):2404-12. doi: 10.1016/S0140-6736(15)00308-6. Epub 2015 Sep 27. Erratum in: Lancet. 2015 Dec 12;386(10011):2394.

13.

The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Rosenblat JD, Kakar R, McIntyre RS.

Int J Neuropsychopharmacol. 2015 Jul 25;19(2). pii: pyv082. doi: 10.1093/ijnp/pyv082. Review.

14.
15.

Enhancement of nootropic effect of duloxetine and bupropion by caffeine in mice.

Kale PP, Addepalli V.

Indian J Pharmacol. 2015 Mar-Apr;47(2):199-201. doi: 10.4103/0253-7613.153430.

16.

Early effects of duloxetine on emotion recognition in healthy volunteers.

Bamford S, Penton-Voak I, Pinkney V, Baldwin DS, Munafò MR, Garner M.

J Psychopharmacol. 2015 May;29(5):634-41. doi: 10.1177/0269881115570085. Epub 2015 Mar 10.

17.

Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment.

Lam RW, Kennedy SH, Mclntyre RS, Khullar A.

Can J Psychiatry. 2014 Dec;59(12):649-54. Review. No abstract available.

18.

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.

Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS.

Neuropsychopharmacology. 2015 Jul;40(8):2025-37. doi: 10.1038/npp.2015.52. Epub 2015 Feb 17.

19.

Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.

Barros BR, Schacht A, Happich M, Televantou F, Berggren L, Walker DJ, Dueñas HJ.

Prim Care Companion CNS Disord. 2014 Oct 2;16(5). doi: 10.4088/PCC.14m01661. eCollection 2014.

20.

The Combination of Antidepressant Duloxetine with Piracetam in Mice does not Produce Enhancement of Nootropic Activity.

Kale PP, Addepalli V, Sarkar A, Patel S, Savai J.

Exp Neurobiol. 2014 Sep;23(3):224-30. doi: 10.5607/en.2014.23.3.224. Epub 2014 Sep 18.

Supplemental Content

Support Center